Barclays’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-11,755
| Closed | -$46.1K | – | 5461 |
|
|
2023
Q3 | $46.1K | Sell |
11,755
-81,438
| -87% | -$556K | ﹤0.01% | 3908 |
|
|
2023
Q2 | $303K | Buy |
93,193
+92,649
| +17,031% | +$275K | ﹤0.01% | 3040 |
|
|
2023
Q1 | $1.97K | Sell |
544
-588
| -52% | -$9.08K | ﹤0.01% | 4893 |
|
|
2022
Q4 | $36.5K | Buy |
1,132
+982
| +655% | +$38.9K | ﹤0.01% | 4654 |
|
|
2022
Q3 | $6K | Buy |
+150
| New | +$6.86K | ﹤0.01% | 4484 |
|
|
2022
Q2 | – | Sell |
-247
| Closed | -$17K | – | 5395 |
|
|
2022
Q1 | $17K | Sell |
247
-1,596
| -87% | -$133K | ﹤0.01% | 4493 |
|
|
2021
Q4 | $224K | Buy |
1,843
+1,222
| +197% | +$206K | ﹤0.01% | 3525 |
|
|
2021
Q3 | $87K | Buy |
621
+429
| +223% | +$85K | ﹤0.01% | 3966 |
|
|
2021
Q2 | $53K | Sell |
192
-771
| -80% | -$195K | ﹤0.01% | 4105 |
|
|
2021
Q1 | $206K | Buy |
963
+640
| +198% | +$177K | ﹤0.01% | 3695 |
|
|
2020
Q4 | $78K | Sell |
323
-129
| -29% | -$16K | ﹤0.01% | 4235 |
|
|
2020
Q3 | $48K | Buy |
452
+60
| +15% | +$5.47K | ﹤0.01% | 4621 |
|
|
2020
Q2 | $38K | Buy |
392
+165
| +73% | +$14.4K | ﹤0.01% | 5039 |
|
|
2020
Q1 | $17K | Sell |
227
-466
| -67% | -$44.4K | ﹤0.01% | 5696 |
|
|
2019
Q4 | $56K | Buy |
693
+352
| +103% | +$39.4K | ﹤0.01% | 5714 |
|
|
2019
Q3 | $41K | Sell |
341
-109
| -24% | -$15K | ﹤0.01% | 5993 |
|
|
2019
Q2 | $81K | Buy |
450
+255
| +131% | +$41.2K | ﹤0.01% | 5847 |
|
|
2019
Q1 | $31K | Buy |
+195
| New | +$38.6K | ﹤0.01% | 6166 |
|
|
2018
Q4 | – | Sell |
-101
| Closed | -$24K | – | 7495 |
|
|
2018
Q3 | $24K | Buy |
101
+81
| +405% | +$21.2K | ﹤0.01% | 6419 |
|
|
2018
Q2 | $5K | Buy |
+20
| New | +$5.83K | ﹤0.01% | 6713 |
|
